Janus Henderson Group PLC Increases Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Janus Henderson Group PLC lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 16.2% during the first quarter, Holdings Channel reports. The fund owned 1,998,875 shares of the biopharmaceutical company’s stock after acquiring an additional 279,108 shares during the period. Janus Henderson Group PLC’s holdings in Catalyst Pharmaceuticals were worth $49,520,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in CPRX. State Street Corp increased its position in shares of Catalyst Pharmaceuticals by 7.8% in the 4th quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock valued at $161,224,000 after purchasing an additional 502,235 shares during the last quarter. Deerfield Management Company L.P. raised its position in shares of Catalyst Pharmaceuticals by 72.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after acquiring an additional 2,095,291 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Catalyst Pharmaceuticals by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after buying an additional 433,318 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 11.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after buying an additional 333,100 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in shares of Catalyst Pharmaceuticals by 59.1% in the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock valued at $68,466,000 after buying an additional 1,089,775 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CPRX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Finally, Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $35.00 to $31.50 in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $31.49 on Friday. The stock has a fifty day moving average of $31.41 and a two-hundred day moving average of $27.60. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).